Insilico Medicine
Generative AI platform for drug discovery, from target to clinic.
About
Insilico Medicine (insilico.com) is a clinical-stage biotech whose Pharma.AI platform uses generative AI across target identification, molecule design, and clinical outcome prediction. Its lead candidate rentosertib (ISM001-055) for idiopathic pulmonary fibrosis has advanced to Phase III — described as a first for an AI-designed drug.
The company lists on the Hong Kong Stock Exchange (03696), reports 30+ assets with 12-18 month preclinical turnarounds, and collaborates with Eli Lilly and Qilu Pharmaceutical. It is a drug R&D platform for biotech and pharma teams, not a tool individual developers deploy; timelines and costs are company-reported.
What it can do
- Pharma.AI end-to-end discovery platform
- Generative molecule design (Chemistry42)
- Target identification (PandaOmics)
- Clinical trial outcome prediction
- Automated wet-lab validation
Setup
- Engage Insilico's business development for platform access or collaboration.
- Define therapeutic area and target profile.
- Run target identification via PandaOmics.
- Generate and optimize molecules via Chemistry42.
- Advance candidates through Insilico's automated lab and trials.
Prerequisites
Pharma/biotech partnership or platform license.
Use cases
Works with
Trust score — 8/10
Scored 8/10 (verified tier, metrics-v1). Evidence: HKEX listed (03696); 30+ assets; rentosertib in Phase III for IPF; 12-18 month preclinical turnaround claimed; Eli Lilly and Qilu collaborations; peer-reviewed publications on generative drug design. Manual review: furthest clinical validation of AI-designed drugs; timelines are company-reported. License: Proprietary platform; pharma partnerships..
How the trust score is built
Full methodology →- Adoption · stars/downloads, log-scaled vs peers
- 8.0/10
- Maintenance · recency, releases, issue load
- 8.0/10
- Openness · license + docs
- 6.0/10
- Manual review · sanity read + red-flag check
- 8.0/10
- · HKEX listed (03696); 30+ assets; rentosertib in Phase III for IPF
- · 12-18 month preclinical turnaround claimed; Eli Lilly and Qilu collaborations
- · peer-reviewed publications on generative drug design
- · manual review: furthest clinical validation of AI-designed drugs; timelines are company-reported
Sources
Every fact above was checked against these sources. Where a claim comes from the provider and couldn't be independently verified, the text says so.